Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
University of Pittsburgh
Study ID
NCT04109820
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • MitoQ — DIETARY_SUPPLEMENT
    Oral; 20mg once a day for 14 days

Study Details

MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).

Key Dates

Start date
Mar 1, 2020
Status verified
Jun 2025
Primary completion
Dec 30, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Sickle cell patients
    Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)
  • Active Comparator: Non Sickle cell Control subjects
    Normal control subjects administered oral MitoQ (20mg once a day for 14 days)

Primary Outcome Measure

Effect of MitoQ on platelet activation markers in subjects with SCA [ Time Frame: Baseline to 14 days ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Children's Hospital of PittsburghPittsburghPennsylvania15224
Mikhil N Bamne, PhD
[email protected]
(412) 648-6920
Jude Jonassaint, RN
[email protected]
(412) 692-2086
Ramasubramanian Kalpatthi, MD (PRINCIPAL_INVESTIGATOR)
Hillman Cancer CenterPittsburghPennsylvania15232
Mikhil N Bamne, PhD
[email protected]
(412) 648-6920
Jude Jonassaint, RN
[email protected]
412-692-2086
Ramasubramanian Kalpatthi, MD (PRINCIPAL_INVESTIGATOR)
Magee Women's HospitalPittsburghPennsylvania15213
Mikhil N Bamne, PhD
[email protected]
(412) 648-6920
Jude Jonassaint, RN
[email protected]
412-692-2086
Ramasubramanian Kalpatthi, MD (PRINCIPAL_INVESTIGATOR)
UPMC MontefiorePittsburghPennsylvania15213
Mikhil N Bamne, PhD
[email protected]
(412) 648-6920
Jude Jonassaint, RN
[email protected]
412-692-2086
Ramasubramanian Kalpatthi, MD (PRINCIPAL_INVESTIGATOR)
UPMC PresbyterianPittsburghPennsylvania15213
Mikhil N Bamne, PhD
[email protected]
(412) 648-6920
Jude Jonassaint, RN
[email protected]
(412) 692-2086
Ramasubramanian Kalpatthi, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Pittsburgh, PA

By condition
Sickle cell disease
By research site
Children's Hospital of Pittsburgh· Pittsburgh, PAHillman Cancer Center· Pittsburgh, PAMagee Women's Hospital· Pittsburgh, PAUPMC Montefiore· Pittsburgh, PAUPMC Presbyterian· Pittsburgh, PA

Related Studies